Delving into the Latest Updates on Daegu Catholic University with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Congenital Disorders

Other Diseases

Small molecule drug

TF Decoy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Endocrinology and Metabolic Disease	2
Neoplasms	1
Infectious Diseases	1
Nervous System Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2
TF Decoy	1

Top 5 Target	Count

PPAR(Peroxisome proliferator activated receptor)	1
HDAC6(Histone deacetylase 6)	1

The goal of this clinical trial is to investigate the effectiveness of photoplethysmographic amplitude in assessing the extent of anesthesia in the 8th cervical dermatome in patients undergoing interscalene brachial plexus block (ISBPB). The main question it aims to answer is
* Is there any difference in the post-block changes in photoplethysmographic amplitude measured from the ipsilateral 5th finger (supplied by the 8th cervical nerve root) between ISBPBs targeting the C5-to-C6 nerve roots and the C5-to-C8 nerve roots?
* Do the changes in photoplethysmographic amplitude represent the extent of anesthesia in the 8th cervical dermatome? Participants will receive either ISBPB targeting the C5-to-C6 nerve roots or the C5-to-C8 nerve roots, and then the changes in photoplethysmographic amplitude will be measured from the 5th finger ipsilateral to ISBPB.

Start Date13 Sep 2023

Sponsor / Collaborator

Daegu Catholic University

KCT0008824

/ RecruitingNot ApplicableIIT

Development and pilot test of web-based preterm birth prevention self-management education program for women of childbearing age

Start Date17 Jul 2023

Sponsor / Collaborator

Daegu Catholic University

100 Clinical Results associated with Daegu Catholic University

Login to view more data

0 Patents (Medical) associated with Daegu Catholic University

Login to view more data

7,574

Literatures (Medical) associated with Daegu Catholic University

01 Jul 2025·Patient Education and Counseling

Development and validation of a menopause-specific health literacy scale for middle-aged women

Article

Author: Kim, Junghee ; Lee, Hanna ; Lee, Haein

OBJECTIVEThis study aimed to develop and validate the Menopause-Specific Health Literacy Scale (Men-HLS) for middle-aged women aged 45-64 years, utilizing an Item Response Theory (IRT) framework and traditional factor analysis.METHODSBased on the four subdomains (access, understand, appraise, and apply) of the integrated health literacy conceptual model proposed by the European Health Literacy Consortium, we developed 73 preliminary items, combining self-reported (subjective) and performance-based (objective) measures. Content validity was assessed by an expert panel (n = 14) and face validity was evaluated by the target population (n = 15). Validity and reliability were evaluated using exploratory factor analysis (EFA), confirmatory factor analysis (CFA), internal consistency, and item analysis based on classical test theory and IRT.RESULTSThe scale was refined to 45 items following content and face validity assessments and reduced to 35 items through classical test theory-based item analysis and inter-item correlation. EFA removed seven cross-loaded items, resulting in three distinct factors: accessing (ACS), appraising (APR), and utilizing (UTL). The IRT analysis demonstrated high item discrimination, with four items in the UTL subdomain showing moderate discrimination. CFA confirmed a good model fit. The final Men-HLS comprised 28 items (6 for ACS, 9 for APR, and 13 for UTL) and achieved a Cronbach's alpha of 0.91.CONCLUSIONSThe Men-HLS is a valid and reliable instrument for identifying health literacy challenges in middle-aged women. Further research is needed to establish its predictive validity through longitudinal data and confirm its measurement invariance across diverse sociodemographic groups.PRACTICE IMPLICATIONSThe Men-HLS provides healthcare professionals with a practical tool for assessing the health literacy levels required to manage menopausal symptoms and chronic conditions, facilitating the development of targeted educational resources and interventions for improved health management.

01 Jun 2025·European Journal of Surgical Oncology

Survival benefit of adjuvant chemotherapy in high-risk patients with colon cancer regardless of microsatellite instability

Article

Author: Park, Soo Yeun ; Jeong, Woon Kyung ; Kim, Min Sung ; Kim, Kyeong Eui ; Park, Youn Young ; Kim, Chang Woo ; Lee, Jong Lyul ; Ha, Gi Won ; Park, Eun Jung ; Yang, Chun-Seok ; Kim, So Hyun ; Kim, Chang Hyun ; Lee, JaeIm ; Son, Gyung Mo ; Lee, Kyung Ha ; Kim, Duck-Woo ; Bae, Sung Uk ; Ji, Woong Bae ; Han, Yoon Dae ; Baek, Seong Kyu

INTRODUCTIONThe predictive utility of high-risk features (HRFs) and microsatellite instability (MSI) status for adjuvant chemotherapy (ACT) in patients with stage II colon cancer remains unclear. We examined the impact of HRFs and MSI in predicting the benefits of adjuvant ACT in patients with stage II colon cancer.MATERIALS AND METHODSWe included 1801 patients with resected stage II colon cancer who underwent ACT (5-fluorouracil [FU] and oxaliplatin) or surgery alone between January 2010 and December 2017. The primary outcomes were overall survival (OS) and disease-free survival (DFS).RESULTSAmong MSI-high patients with HRFs, patients who received 5- FU and oxaliplatin-based ACT had significantly higher OS and DFS than patients who did not, with no significant difference between those who received 5-FU and oxaliplatin as ACT. Among MSI-low/microsatellite stable patients with HRFs, patients who received 5-FU and oxaliplatin as ACT had significantly higher OS and DFS than patients who did not, with no significant differences between those who received 5-FU and oxaliplatin as ACT. Among patients who did not receive ACT, OS and DFS were 95.0 % and 91.2 % for patients without HRFs, respectively, and 84.4 % and 75.0 % for patients with HRFs, respectively. ACT improved the survival rates of patients with HRFs (OS: 84.4 %→95.9 %, DFS: 75.0 %→88.9 %).CONCLUSIONSACT can be recommended for patients having stage II colon cancer with one or more HRF(s) for recurrence, regardless of the MSI status. In patients with HRFs, we observed no significant difference regarding survival between those who received 5-FU and oxaliplatin-based ACT.

30 Apr 2025·Endocrinology and Metabolism

Advances in Continuous Glucose Monitoring: Clinical Applications

Article

Author: Kwon, So Yoon ; Moon, Jun Sung

Continuous glucose monitoring (CGM) has revolutionized diabetes management, significantly enhancing glycemic control across diverse patient populations. Recent evidence supports its effectiveness in both type 1 and type 2 diabetes management, with benefits extending beyond traditional glucose monitoring approaches. CGM has demonstrated substantial improvements in glycemic control across multiple metrics. Studies report consistent glycosylated hemoglobin reductions of 0.25%–3.0% and notable time in range improvements of 15%–34%. CGM effectively reduces hypoglycemic events, with studies reporting significant reductions in time spent in hypoglycemia. CGM also serves as an educational tool for lifestyle modification, providing real-time feedback that helps patients understand how diet and physical activity affect glucose levels. While skin-related complications remain a concern, technological advancements have addressed many initial concerns. High satisfaction rates and long-term use suggest that device-related issues are manageable with proper education and support. Despite high initial costs, CGM’s prevention of complications and hospitalizations ultimately reduces healthcare expenditures. With appropriate training and support, CGM represents a transformative technology for comprehensive diabetes care.

100 Deals associated with Daegu Catholic University

Login to view more data

100 Translational Medicine associated with Daegu Catholic University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

Login to view more data